CODEINE PHOSPHATE INJECTION USP LIQUID

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

CODEINE PHOSPHATE

Доступна с:

SANDOZ CANADA INCORPORATED

код АТС:

R05DA04

ИНН (Международная Имя):

CODEINE

дозировка:

30MG

Фармацевтическая форма:

LIQUID

состав:

CODEINE PHOSPHATE 30MG

Администрация маршрут:

INTRAMUSCULAR

Штук в упаковке:

10X1ML/25X1ML

Тип рецепта:

Narcotic (CDSA I)

Терапевтические области:

OPIATE AGONISTS

Обзор продуктов:

Active ingredient group (AIG) number: 0104398004; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2005-08-11

Характеристики продукта

_Codeine Phosphate Injection USP _
_ _
_Page 1 of 34 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
CODEINE PHOSPHATE INJECTION USP
Codeine Phosphate
Solution for Injection 30mg/mL
USP
Opioid Analgesic–Antitussive
Sandoz Canada Inc.
Date of Revision:
110 Rue de Lauzon
December 16, 2019
Boucherville, QC, Canada
J4B 1E6
Submission Control No: 225996
_Codeine Phosphate Injection USP _
_ _
_Page 2 of 34 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................13
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................18
OVERDOSAGE
................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................22
STORAGE AND STABILITY
..........................................................................................23
SPECIAL HANDLING INSTRUCTIONS
.......................................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................24
PART II: SCIENTIFIC INFORMATION
...............................................................................25
PHARMACEUTICAL INFORMATION
..........................................................................25
PART III: CONSUMER MEDICATION INFORMATION
..................................................26
_